DALLAS, March 15, 2023 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic rare diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2022, and host a corporate update conference call and webcast on Tuesday, March 28, 2023, at 4:30 PM Eastern Time.
|Conference Call Details|
|Tuesday, March 28, at 4:30 PM Eastern Time / 3:30 PM Central Time|
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
Kimberly Lee, D.O.
Chief Corporate Affairs Officer
Taysha Gene Therapies
- New Report from the WatchGuard Threat Lab Shows Surge in Endpoint Ransomware, Decline in Network-Detected Malware - March 29, 2023
- Hardware Wallet Market is anticipated to progress at a CAGR of 24.9% from 2023 to 2030, Data By Contrive Datum Insights - March 29, 2023
- Pie Packaging Market is projected to Reach US$ 84.27 Billion by 2030, at a CAGR of 6.0% during the forecast period 2023-2030, Data By Contrive Datum Insights - March 29, 2023